Meet our Executive Team
Peter M. Melnyk
Chief Executive Officer
Peter M. Melnyk joined Fortovia Therapeutics as Chief Executive Officer in June 2019. Mr. Melnyk has over 25+ years of experience in Oncology commercialization. Prior to Fortovia Therapeutics, Mr. Melnyk served as Chief Commercial Officer with Novocure Inc. from 2011 through 2017, with overall responsibility for directing the company’s global sales and marketing efforts. Mr. Melnyk was previously Senior Vice President for Global Sales and Marketing at OSI Pharmaceuticals, Inc., where he led the global commercialization efforts for Tarceva from 2003 to 2011. Prior to OSI, Mr. Melnyk was executive director of oncology at Pharmacia/Pfizer Inc. and a director of oncology at Bristol-Myers Squibb. Mr. Melnyk started his career with Leo Laboratories and Burroughs-Welcome in Canada. Mr. Melnyk holds a B.Sc. and M.Sc. from McGill University.
Ernie De Paolantonio
Chief Financial Officer
Ernie De Paolantonio joined Fortovia as CFO in May 2019. He has over 35 years of varied financial and business experience in the pharmaceutical industry. From 2013-2019, he was CFO of BioDelivery Sciences International (NASDAQ:BDSI), a publicly traded pharmaceutical company with three marketed specialty branded products. He led the finance organization and was also responsible for the supply chain function. From 2008-2013, Mr. De Paolantonio served as the CFO of CorePharma LLC, a private specialty generic company. Mr. De Paolantonio was the Corporate Controller at both Colombia Laboratories and Taro Pharmaceuticals, and was Executive Director at Watson Pharmaceuticals managing the Corporation’s supply chain. He began his career at GlaxoSmithKline in finance and spent over 17 years in positions of increasing responsibility. Mr. De Paolantonio received his BA from Lycoming College; his MBA in Finance from Saint Joseph’s University and is also a CPA.
General Counsel & Chief Compliance Officer
With more than 17 years in the pharmaceutical industry, Mr. Petrolino has worked in a number of positions of increasing responsibility in the legal and compliance departments of publicly traded pharmaceutical and biotechnology companies including Novartis, Progenics Pharmaceuticals, Savient Pharmaceuticals, DARA BioSciences and, most recently, Midatech Pharma PLC. Mr. Petrolino has been responsible for advising Boards of Directors and senior management on matters ranging from mergers and acquisitions and product licensing activity to corporate governance elements to risk management. He has managed legal departments with oversight responsibilities for execution of all forms of agreements and has worked in close collaboration with all corporate functions inside fully integrated biotechnology companies. Mr. Petrolino has managed the creation, implementation and oversight of robust corporate compliance programs at multiple organizations.
Mary Kay Delmedico, PhD
Vice President of Scientific & Regulatory Affairs
Having dedicated more than 25 years to the biopharmaceutical industry, Dr. Delmedico has held senior leadership roles in support of scientific, clinical, regulatory, commercial, and strategic objectives at Trimeris, Inc., DARA BioSciences, and Midatech Pharma US Inc. She has been an integral part of product design and development from early discovery through clinical development and commercialization. Dr. Delmedico holds a B.S. from St. Edwards University and a Ph.D. in chemistry from the University of California, Berkeley.